CA3134764A1 - Compositions and methods for use of cannabinoids for neuroprotection - Google Patents
Compositions and methods for use of cannabinoids for neuroprotection Download PDFInfo
- Publication number
- CA3134764A1 CA3134764A1 CA3134764A CA3134764A CA3134764A1 CA 3134764 A1 CA3134764 A1 CA 3134764A1 CA 3134764 A CA3134764 A CA 3134764A CA 3134764 A CA3134764 A CA 3134764A CA 3134764 A1 CA3134764 A1 CA 3134764A1
- Authority
- CA
- Canada
- Prior art keywords
- neuroprotective
- neuroprotective compound
- composition
- compound
- neuron
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/78—Ring systems having three or more relevant rings
- C07D311/80—Dibenzopyrans; Hydrogenated dibenzopyrans
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Ophthalmology & Optometry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Dispersion Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962838216P | 2019-04-24 | 2019-04-24 | |
| US62/838,216 | 2019-04-24 | ||
| PCT/CA2020/050547 WO2020215164A1 (en) | 2019-04-24 | 2020-04-24 | Compositions and methods for use of cannabinoids for neuroprotection |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3134764A1 true CA3134764A1 (en) | 2020-10-29 |
Family
ID=72940570
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3134764A Pending CA3134764A1 (en) | 2019-04-24 | 2020-04-24 | Compositions and methods for use of cannabinoids for neuroprotection |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230043428A1 (https=) |
| EP (1) | EP3958856A4 (https=) |
| JP (1) | JP7633179B2 (https=) |
| KR (1) | KR20220080045A (https=) |
| CN (1) | CN114007603A (https=) |
| AU (1) | AU2020261515B2 (https=) |
| CA (1) | CA3134764A1 (https=) |
| IL (1) | IL287536B2 (https=) |
| MX (1) | MX2021012960A (https=) |
| SG (1) | SG11202111809XA (https=) |
| WO (1) | WO2020215164A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115006404A (zh) * | 2022-08-09 | 2022-09-06 | 昆药集团股份有限公司 | 一种具有视神经保护功效的药物组合物及其应用 |
| WO2024091653A1 (en) * | 2022-10-27 | 2024-05-02 | Kemin Industries, Inc. | Use of a spearmint extract for retina neurotrophism |
| WO2024148117A2 (en) * | 2023-01-04 | 2024-07-11 | Florascience Inc. | Methods of treating neurodegenerative diseases or conditions |
| WO2025090133A1 (en) * | 2023-10-23 | 2025-05-01 | Inmed Pharmaceuticals Inc. | Compositions and methods for use of cannabinol compounds in neuroprotection |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2471987B (en) * | 2008-06-04 | 2012-02-22 | Gw Pharma Ltd | Anti-tumoural effects of cannabinoid combinations |
| EP2640379A4 (en) * | 2010-11-18 | 2014-08-13 | Pier Pharmaceuticals | LOW DOSED CANNABINOIDARY MEDICINES |
| BR122021018502B1 (pt) * | 2014-10-21 | 2022-05-03 | United Cannabis Corp | Formulação de canabinoide líquida |
| MA41299A (fr) * | 2014-12-30 | 2017-11-07 | Axim Biotechnologies Inc | Solutions ophtalmiques pour le traitement du glaucome et de la conjonctivite |
| CN107405314A (zh) * | 2015-02-27 | 2017-11-28 | 埃布公司 | 包含纯化的大麻素与至少一种类黄酮、萜或矿物质的组合的组合物 |
| AU2016225026A1 (en) * | 2015-02-27 | 2017-09-07 | Canopy Growth Corporation | Compositions comprising combinations of purified cannabinoids, with at least one flavonoid, terpene, or mineral |
| US20170266153A1 (en) * | 2015-02-27 | 2017-09-21 | Ebbu, LLC | Compositions purposefully selected comprising purified cannabinoids and/or purified terpenes |
| US20160282371A1 (en) * | 2015-03-28 | 2016-09-29 | Quantalytical Labs Inc. | Solid Phase Extraction, Derivatization with Crown Ethers, and Mass Spectrometry, Methods, Reagents and Kits |
| IL248149B (en) * | 2016-09-29 | 2020-03-31 | Garti Nissim | Dilutable formulations of cannbinoids and processes for their preparation |
| CN109963595B (zh) * | 2016-10-11 | 2023-02-03 | Gbs全球生物制药公司 | 用于治疗神经退行性疾病的含有大麻素的复合混合物 |
| WO2018118197A1 (en) * | 2016-12-21 | 2018-06-28 | Richard Postrel | Healthier aging in domesticated animals |
| WO2018205022A1 (en) * | 2017-05-08 | 2018-11-15 | Inmed Pharmaceuticals Inc. | Ocular drug delivery formulation |
| WO2018205038A1 (en) * | 2017-05-12 | 2018-11-15 | Tetra Bio-Pharma Inc. | Compositions comprising cannabinoids and terpenes useful in the treatment of cancer and vascular ocular disorders via inhibition of hedgehog signalling |
| US20170348277A1 (en) * | 2017-08-02 | 2017-12-07 | Bryan Ray Ruiz | Cannabinoid formulation including a vasodilator and ocular delivery of the same |
-
2020
- 2020-04-24 KR KR1020217036628A patent/KR20220080045A/ko not_active Withdrawn
- 2020-04-24 EP EP20794650.0A patent/EP3958856A4/en active Pending
- 2020-04-24 IL IL287536A patent/IL287536B2/en unknown
- 2020-04-24 JP JP2021563360A patent/JP7633179B2/ja active Active
- 2020-04-24 CN CN202080046190.4A patent/CN114007603A/zh active Pending
- 2020-04-24 SG SG11202111809XA patent/SG11202111809XA/en unknown
- 2020-04-24 US US17/606,003 patent/US20230043428A1/en active Pending
- 2020-04-24 CA CA3134764A patent/CA3134764A1/en active Pending
- 2020-04-24 MX MX2021012960A patent/MX2021012960A/es unknown
- 2020-04-24 WO PCT/CA2020/050547 patent/WO2020215164A1/en not_active Ceased
- 2020-04-24 AU AU2020261515A patent/AU2020261515B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| IL287536A (en) | 2021-12-01 |
| AU2020261515A1 (en) | 2021-11-18 |
| WO2020215164A1 (en) | 2020-10-29 |
| EP3958856A4 (en) | 2023-01-25 |
| IL287536B2 (en) | 2026-03-01 |
| US20230043428A1 (en) | 2023-02-09 |
| SG11202111809XA (en) | 2021-11-29 |
| IL287536B1 (en) | 2025-11-01 |
| JP2022530471A (ja) | 2022-06-29 |
| JP7633179B2 (ja) | 2025-02-19 |
| AU2020261515B2 (en) | 2025-10-23 |
| KR20220080045A (ko) | 2022-06-14 |
| EP3958856A1 (en) | 2022-03-02 |
| CN114007603A (zh) | 2022-02-01 |
| MX2021012960A (es) | 2022-01-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2020261515B2 (en) | Compositions and methods for use of cannabinoids for neuroprotection | |
| JP6060168B2 (ja) | レバミピドと涙液保持作用を有する薬剤からなる前眼部疾患治療剤 | |
| EP2646010B1 (en) | Folic acid - ramipril combination: cellprotective, neuroprotective and retinoprotective ophtalmologic compositions | |
| ES2324130A1 (es) | Uso de derivados de mononitrato de dianhidrohexita como agentes antiinflamatorios y reductores de la hipertension ocular. | |
| WO2005055926A2 (en) | Amelioration of cataracts, macular degeneration and other ophthalmic diseases | |
| AU2005237543B2 (en) | Statins for the treatment of ocular hypertension and glaucoma | |
| US20230381205A1 (en) | Compositions and methods for treating neuronal disorders with cannabinoids | |
| US20240261273A1 (en) | Pridopidine and analogs thereof for the treatment of neurodegenerative eye disease | |
| JP7834370B2 (ja) | 緑内障の治療のためのカルパイン－２選択的阻害剤化合物 | |
| AU778148B2 (en) | 2-aminotetralin derivatives for the therapy of glaucoma | |
| WO2025090133A1 (en) | Compositions and methods for use of cannabinol compounds in neuroprotection | |
| WO2025090587A1 (en) | Cannabinoids compounds and their use in the treatment of neuronal disorders | |
| US20080318939A1 (en) | Methods for treating ophthalmic disorders | |
| Kobayashi et al. | 152. Neuroprotection Organizing Section: PH Contributing Section: RC | |
| Sgambellone et al. | Special Focus on Glaucoma | |
| HK1190067B (en) | Folic acid - ramipril combination: cellprotective, neuroprotective and retinoprotective ophtalmologic compositions | |
| HK1102913B (en) | Statins for the treatment of ocular hypertension and glaucoma | |
| HK1241269B (zh) | 前列腺素类和一氧化氮供体的组合产品 | |
| ZA200604402B (en) | Amelioration of cataracts, macular degeneration and other ophthalmic diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20240423 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD Year of fee payment: 5 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250402 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250402 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20251124 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20260324 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20260330 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20260330 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20260330 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD Year of fee payment: 6 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20260422 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20260422 |